June 15, 2020
IBRI IN THE NEWS: Biosciences Institute Develops Diagnosis Technologies
INDIANAPOLIS - The Indiana Biosciences Research Institute in Indianapolis has completed development of two technologies it says could diagnose diseases faster and with more accuracy. The IBRI says its BioMEMs...
June 11, 2020
IBRI Develops Technologies that Help to Diagnose Diseases Faster, More Accurately
INDIANAPOLIS, IND. - The Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, is pleased to announce that it has completed development of two technologies – BioMEMs...
June 09, 2020
IBRI and TBH Creative Win Gold Aster Award
We were pleased to partner with TBH Creative to move our 2018 Annual Report from print to online. TBH Creative took the PDF and transformed it into its own microsite...
June 03, 2020
IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes
Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between...
May 29, 2020
IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine
The race is on.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories scrambling to find a way to slow...
May 26, 2020
New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D
INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes...
May 13, 2020
IBRI RESEARCH PUBLISHED: Pancreatic ß-cells in Type 1 and Type 2 Diabetes Mellitus: Different Pathways to Failure
Loss of functional β-cell mass is the key mechanism leading to the two main forms of diabetes mellitus — type 1 diabetes mellitus (T1DM) and type 2 diabetes...
April 21, 2020
IBRI RESEARCH PUBLISHED: SUMOylation, a multifaceted regulatory mechanism in the pancreatic beta cells
SUMOylation is an evolutionarily conserved post-translational modification (PTM) that regulates protein subcellular localization, stability, conformation, transcription and enzymatic activity. Recent studies indicate that SUMOylation plays a key role...
April 16, 2020
IBRI IN THE NEWS: IBRI Names Scientific Director
INDIANAPOLIS - The Indiana Biosciences Research Institute has named Investigator Decio Eizirik as Scientific Director of the IBRI Diabetes Center. Eizirik will focus on recruiting early career investigators and defining...
April 15, 2020
IBRI Names Decio Eizirik Scientific Director of its IBRI Diabetes Center
INDIANAPOLIS, IND. – The Indiana Biosciences Research Institute (IBRI) is pleased to announce that it has named Investigator Decio Eizirik, MD, PhD, Scientific Director of its IBRI Diabetes Center (IDC)....
First 1 2 3 4 5 ... Last